Weekly update|Companies|Recruiting|Promote|Post a job

QurAlis

Founded: 2016

Location: Cambridge, MA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: ALS

Drug types: NEU

Lead product: QRL-201

Product link: https://quralis.com/pipeline/

Funding: $88M B Mar 2023; $42M May 2020; $5.5M Seed Nov 2018

Investors: EQT Life Sciences, Droia Ventures, Sanofi Ventures, BioInnovation Capital, Viva Biotech Limited, Alexandria, Amgen, MP Healthcare Venture Management, ALS Investment Fund, LS Polaris Innovation Fund, Mission BioCapital, INKEF Capital, Dementia Discovery Fund, Amgen Ventures, MP Healthcare Venture Management, Mitsui Global Investment, Dolby Family Ventures, Mission Bay Capital, Sanford Biosciences

quralis.com

linkedin.com

job board

Short description:

ALS cure - Small Molecules, ASO

Drug notes:

QRL-201/QRL-203 Clin0 FTD, Clin0 PLS; QRL-101 Clin1 ALS, Clin0 FTD; QRL-204 Clin0 ALS/FTD, Clin0 FTD

Long description:

QurAlis is using advances in precision medicine to develop therapeutics for neurodegenerative diseases. Amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative disease that reduces muscle function and control. By examining the disease-causing genetic alterations linked with ALS, QurAlis is targeting these disease mechanisms using human neuronal stem cell models from ALS patients - this includes the gene that encodes the protein TDP-43. QuAlis has a second platform, FlexASO, a proprietary anti-sense oligonucleotide splice modulator platform to selectively modulate RNA levels to change the expression of genes connected to disease. With these approaches, QurAlis has already established a pipeline of programs in clinical stages.